Khaemba, C.; Barry, A.; Omondi, W.P.; Bota, K.; Matendechero, S.; Wandera, C.; Siyoi, F.; Kirui, E.; Oluka, M.; Nambwa, P.;
et al. Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. Pharmaceuticals 2021, 14, 264.
https://doi.org/10.3390/ph14030264
AMA Style
Khaemba C, Barry A, Omondi WP, Bota K, Matendechero S, Wandera C, Siyoi F, Kirui E, Oluka M, Nambwa P,
et al. Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. Pharmaceuticals. 2021; 14(3):264.
https://doi.org/10.3390/ph14030264
Chicago/Turabian Style
Khaemba, Christabel, Abbie Barry, Wyckliff P. Omondi, Kefa Bota, Sultani Matendechero, Cecilia Wandera, Fred Siyoi, Elvis Kirui, Margaret Oluka, Pamela Nambwa,
and et al. 2021. "Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study" Pharmaceuticals 14, no. 3: 264.
https://doi.org/10.3390/ph14030264
APA Style
Khaemba, C., Barry, A., Omondi, W. P., Bota, K., Matendechero, S., Wandera, C., Siyoi, F., Kirui, E., Oluka, M., Nambwa, P., Gurumurthy, P., Njenga, S. M., Guantai, A., & Aklillu, E.
(2021). Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. Pharmaceuticals, 14(3), 264.
https://doi.org/10.3390/ph14030264
